Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1235-1245

  Takane, Kiyoko ^a,b   Midorikawa, Yutaka ^a,c   Yagi, Koichi ^d   Sakai, Ayako ^c,e   Aburatani, Hiroyuki ^c   Takayama, Tadatoshi ^a   Kaneda, Atsushi ^b,c,f  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SYSMEX CORPORATION   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Biomarker; Cancer detection; Colorectal cancer; DNA methylation; Plasma DNA

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARRIER PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PPP1R3C PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; EFHD1 GENE; FEMALE; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PPP1R3C GENE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR GENE; ADULT; BLOOD; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPROTEIN PHOSPHATASES; PROMOTER REGIONS, GENETIC;

EID: 84991491983     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.273     Document Type: Article

References (29)

1. Fenlon, H. M., D. P. Nunes, P. C. Schroy, III, M. A. Barish, P. D. Clarke, and J. T. Ferrucci. 1999. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N. Engl. J. Med. 341:1496-1503.
2. Quintero, E., A. Castells, L. Bujanda, J. Cubiella, D. Salas, A. Lanas, et al. 2012. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366:697-706.
3. Nakayama, Y., T. Torigoe, N. Minagawa, and K. Yamaguchi. 2012. The clinical usefulness of urinary N(1), N(12)-diacetylspermine (DiAcSpm) levels as a tumor marker in patients with colorectal cancer. Oncol. Lett. 3:970-974.
4. Laird, P. W. 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3:253-266.
5. Muller, H. M., M. Oberwalder, H. Fiegl, M. Morandell, G. Goebel, M. Zitt, et al. 2004. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363:1283-1285.
6. Schwarzenbach, H., D. S. Hoon, and K. Pantel. 2011. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11:426-437.
7. Vasioukhin, V., P. Anker, P. Maurice, J. Lyautey, C. Lederrey, and M. Stroun. 1994. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 86:774-779.
8. Nawroz, H., W. Koch, P. Anker, M. Stroun, and D. Sidransky. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2:1035-1037.
9. Jones, P. A., and S. B. Baylin. 2007. The epigenomics of cancer. Cell 128:683-692.
10. Esteller, M. 2008. Epigenetics in cancer. N. Engl. J. Med. 358:1148-1159.
11. Lofton-Day, C., F. Model, T. Devos, R. Tetzner, J. Distler, M. Schuster, et al. 2008. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54:414-423.
12. Warren, J. D., W. Xiong, A. M. Bunker, C. P. Vaughn, L. V. Furtado, W. L. Roberts, et al. 2011. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9:133.
13. Toyota, M., N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J. P. Issa. 1999. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96:8681-8686.
14. Weisenberger, D. J., K. D. Siegmund, M. Campan, J. Young, T. I. Long, M. A. Faasse, et al. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38:787-793.
15. Yagi, K., K. Akagi, H. Hayashi, G. Nagae, S. Tsuji, T. Isagawa, et al. 2010. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16:21-33.
16. Ogino, S., T. Kawasaki, G. J. Kirkner, M. Loda, and C. S. Fuchs. 2006. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 8:582-588.
17. Shen, L., M. Toyota, Y. Kondo, E. Lin, L. Zhang, Y. Guo, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104:18654-18659.
18. Hinoue, T., D. J. Weisenberger, C. P. Lange, H. Shen, H. M. Byun, D. Van Den Berg, et al. 2012. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22:271-282.
19. Herman, J. G., J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin. 1996. Methylation-specific PCR, a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93:9821-9826.
20. Colella, S., L. Shen, K. A. Baggerly, J. P. Issa, and R. Krahe. 2003. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150.
21. Kawakami, K., J. Brabender, R. V. Lord, S. Groshen, B. D. Greenwald, M. J. Krasna, et al. 2000. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 92:1805-1811.
22. Ehrich, M., M. R. Nelson, P. Stanssens, M. Zabeau, T. Liloglou, G. Xinarianos, et al. 2005. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl Acad. Sci. USA 102:15785-15790.
23. Matsusaka, K., A. Kaneda, G. Nagae, T. Ushiku, Y. Kikuchi, R. Hino, et al. 2011. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71:7187-7197.
24. Chen, W. D., Z. J. Han, J. Skoletsky, J. Olson, J. Sah, L. Myeroff, et al. 2005. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97:1124-1132.
25. Toth, K., F. Sipos, A. Kalmar, A. V. Patai, B. Wichmann, R. Stoehr, et al. 2012. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7:e46000.
26. Grutzmann, R., B. Molnar, C. Pilarsky, J. K. Habermann, P. M. Schlag, H. D. Saeger, et al. 2008. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3:e3759.
27. deVos, T., R. Tetzner, F. Model, G. Weiss, M. Schuster, J. Distler, et al. 2009. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55:1337-1346.
28. Church, T. R., M. Wandell, C. Lofton-Day, S. J. Mongin, M. Burger, S. R. Payne, et al. 2014. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63:317-325.
29. Yagi, K., H. Takahashi, K. Akagi, K. Matsusaka, Y. Seto, H. Aburatani, et al. 2012. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am. J. Pathol. 180:616-625.